Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C34H31F3N2O2 |
| Molecular Weight | 556.6173 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(C=CC=C1)[C@H](C2=CC=CC3=C2C=CC=C3)[C@@](C)(C#N)C(=O)N4CCC(CC4)C5=CC(=CC=C5)C(F)(F)F
InChI
InChIKey=JZPONCMNBSEYQW-CQTOTRCISA-N
InChI=1S/C34H31F3N2O2/c1-33(22-38,32(40)39-19-17-23(18-20-39)25-11-7-12-26(21-25)34(35,36)37)31(29-14-5-6-16-30(29)41-2)28-15-8-10-24-9-3-4-13-27(24)28/h3-16,21,23,31H,17-20H2,1-2H3/t31-,33+/m0/s1
| Molecular Formula | C34H31F3N2O2 |
| Molecular Weight | 556.6173 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: http://adisinsight.springer.com/drugs/800022078https://www.ncbi.nlm.nih.gov/pubmed/29067315 | https://www.ncbi.nlm.nih.gov/pubmed/24489014 | https://adisinsight.springer.com/drugs/800029247Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/16317384 | https://www.ncbi.nlm.nih.gov/pubmed/17902637
Sources: http://adisinsight.springer.com/drugs/800022078https://www.ncbi.nlm.nih.gov/pubmed/29067315 | https://www.ncbi.nlm.nih.gov/pubmed/24489014 | https://adisinsight.springer.com/drugs/800029247
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/16317384 | https://www.ncbi.nlm.nih.gov/pubmed/17902637
Juvantia Pharma and Orion developed ORM-12741, also known as ORM-10921, a novel selective antagonist of alpha-2C adrenoceptors for the treatment of depression and Alzheimer's disease. ORM-12741 participated in phase II clinical trial where was evaluated the safety and efficacy of the drug in patients with Alzheimer's disease. In spite of the successfully completed phase II, further study of the drug for this disease was discontinued. In addition, ORM-12741 participated in clinical trial phase II to prove the concept that this drug could prevent blood vessel spasms for Raynaud's phenomenon. Raynaud's phenomenon is a disorder of the digital blood vessels resulting in episodic impairment of blood flow. However, this study was terminated because of the recommendation by study Data and Safety Monitoring Committee to the sponsor following the interim analysis of 8 subjects.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| The α2C-adrenoceptor antagonist, ORM-10921, exerts antidepressant-like effects in the Flinders Sensitive Line rat. | 2017-02 |
|
| Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer's disease. | 2017-01 |
|
| Therapeutic Potential of Selectively Targeting the α2C-Adrenoceptor in Cognition, Depression, and Schizophrenia-New Developments and Future Perspective. | 2017 |
|
| The α2C-adrenoceptor antagonist, ORM-10921, has antipsychotic-like effects in social isolation reared rats and bolsters the response to haloperidol. | 2016-11-03 |
|
| A double-blind, randomized, placebo-controlled crossover trial of the α2C-adrenoceptor antagonist ORM-12741 for prevention of cold-induced vasospasm in patients with systemic sclerosis. | 2014-05 |
|
| Estrogen receptor dependent inhibitors of NF-kappaB transcriptional activation-1 synthesis and biological evaluation of substituted 2-cyanopropanoic acid derivatives: pathway selective inhibitors of NF-kappaB, a potential treatment for rheumatoid arthritis. | 2007-11-01 |
|
| The activity of pathway-selective estrogen receptor ligands in experimental septic shock. | 2005-12 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:02:20 GMT 2025
by
admin
on
Mon Mar 31 18:02:20 GMT 2025
|
| Record UNII |
QT9VF4MW6U
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9829162
Created by
admin on Mon Mar 31 18:02:20 GMT 2025 , Edited by admin on Mon Mar 31 18:02:20 GMT 2025
|
PRIMARY | |||
|
WAY-204688
Created by
admin on Mon Mar 31 18:02:20 GMT 2025 , Edited by admin on Mon Mar 31 18:02:20 GMT 2025
|
PRIMARY | |||
|
QT9VF4MW6U
Created by
admin on Mon Mar 31 18:02:20 GMT 2025 , Edited by admin on Mon Mar 31 18:02:20 GMT 2025
|
PRIMARY | |||
|
DTXSID701336370
Created by
admin on Mon Mar 31 18:02:20 GMT 2025 , Edited by admin on Mon Mar 31 18:02:20 GMT 2025
|
PRIMARY | |||
|
796854-35-8
Created by
admin on Mon Mar 31 18:02:20 GMT 2025 , Edited by admin on Mon Mar 31 18:02:20 GMT 2025
|
PRIMARY | |||
|
SIM-688
Created by
admin on Mon Mar 31 18:02:20 GMT 2025 , Edited by admin on Mon Mar 31 18:02:20 GMT 2025
|
PRIMARY | HY-19498 CAS:796854-35-8 (Synonyms WAY 204688, WAY204688, SIM 688, SIM688, SIM-688) |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Class: Fluorobenzenes, Nitrile, Piperidine; Mechanism of Action: Estrogen receptor agonist, NF-kappa B inhibitor; Highest Development Phase: Discontinued for Rheumatoid arthritis; Most Recent Event: 11 Jan 2005 Phase-I clinical trials in Rheumatoid arthritis in USA (PO)
|
